Sinopharm Group reports increased assets, slight profit rise in Q3

Sinopharm Group Co. Ltd. announced its financial information for the nine months ended September 30, 2025, revealing a total operating revenue of RMB431.48 bn, compared to RMB442.42 bn for the same period in 2024. The net profit attributable to equity holders of the parent reached RMB5.31 bn, a slight increase from RMB5.28 bn in the prior year. Basic and diluted earnings per share were RMB1.70, up from RMB1.69 in 2024.

The Group's total assets as of September 30, 2025, stood at RMB418.38 bn, an increase from RMB392.67 bn as of December 31, 2024. Total owners' equity also rose to RMB132.17 bn from RMB126.91 bn. Net cash flows used in operating activities amounted to RMB(39.08 bn).

For the Company alone, total operating revenue was RMB15.54 bn, with a net profit of RMB1.21 bn for the nine months ended September 30, 2025. Total assets for the Company were RMB76.93 bn, and total owners' equity was RMB32.38 bn.